LB Pharmaceuticals IncLBRX stock score: 41/100
$40.04 · -0.05% · Scored Nov 19, 2026
- Technical
- 54
- Fundamental
- 37
- News
- 51
The reading
LB Pharmaceuticals (LBRX) scores 41 out of 100, which reads weak, higher than 26% of Healthcare stocks and 24% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 37, technicals 54.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Quality (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 52 and contrarian oscillators 51.
News sentiment is neutral at 51; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 39 to 57, and it is down 15 points over the period.
About LB Pharmaceuticals
LB Pharmaceuticals (LBRX) is a clinical-stage biopharmaceutical company developing new treatments for schizophrenia and other neuropsychiatric disorders. Its lead candidate, LB-102, is a once-daily oral drug from the benzamide class, related to amisulpride, an antipsychotic used outside the United States that has not been approved here for psychiatric use. LB-102 is designed to block dopamine and serotonin receptors involved in psychosis, and in a mid-stage trial it reduced schizophrenia symptoms compared with placebo, with results published in a major psychiatry journal. The company is running a pivotal late-stage trial in adults with acute schizophrenia and plans to study LB-102 in major depressive disorder as an add-on therapy, as well as in negative symptoms of schizophrenia and psychosis related to Alzheimer’s disease. LB Pharmaceuticals has no product revenue and funds research with cash raised from investors.
In schizophrenia, LB Pharmaceuticals would compete with established antipsychotics from Johnson & Johnson, AbbVie, Otsuka and Lundbeck, as well as Bristol Myers Squibb’s Cobenfy and many generic drugs. Its edge rests on a drug class with a long record of use in other countries, potential benefits on cognition and a possible first U.S. approval for a benzamide antipsychotic. Investors who follow LBRX stock tend to watch enrollment and topline results from the pivotal schizophrenia trial. Safety and tolerability findings are closely followed. Plans for depression and other indications, partnering and cash runway are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward LBRX’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
37Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
How often the company beat analysts' EPS estimates over recent quarters, by how much, and the trend in reported EPS from quarter to quarter.
5-year earnings growth evaluates long-term profit trajectory and consistency.
Net income growth against the same quarter a year earlier, weighted toward the latest quarter.
26 weighted scorers; 13 had no data today and are left out rather than counted as zero.
Technical · daily
55Pulling it up
Where the close sits against its 50-day EMA.
Where the close sits against its 100-day SMA.
The price change over the last 52 weeks.
Holding it back
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
Simple Moving Average (10-period) smooths price action over 10 periods.
SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 51
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 47 | 1 |
| Daily | 55 | 3 |
| Weekly | 56 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 41 |
| Nov 18, 2026 | 41 |
| Nov 17, 2026 | 40 |
| Nov 15, 2026 | 42 |
| Nov 14, 2026 | 42 |
| Nov 13, 2026 | 42 |
| Nov 12, 2026 | 39 |
| Nov 11, 2026 | 55 |
| Nov 10, 2026 | 54 |
| Nov 7, 2026 | 53 |
| Nov 6, 2026 | 53 |
| Nov 5, 2026 | 50 |
| Nov 4, 2026 | 54 |
| Nov 3, 2026 | 54 |
| Nov 2, 2026 | 51 |
| Nov 1, 2026 | 53 |
| Oct 30, 2026 | 53 |
| Oct 29, 2026 | 52 |
| Oct 27, 2026 | 52 |
| Oct 26, 2026 | 52 |
| Oct 25, 2026 | 51 |
| Oct 24, 2026 | 51 |
| Oct 23, 2026 | 51 |
| Oct 22, 2026 | 53 |
| Oct 21, 2026 | 52 |
| Oct 20, 2026 | 54 |
| Oct 19, 2026 | 52 |
| Oct 18, 2026 | 51 |
| Oct 17, 2026 | 51 |
| Oct 16, 2026 | 51 |
| Oct 15, 2026 | 50 |
| Oct 14, 2026 | 48 |
| Oct 13, 2026 | 49 |
| Oct 12, 2026 | 50 |
| Oct 11, 2026 | 51 |
| Oct 10, 2026 | 51 |
| Oct 9, 2026 | 51 |
| Oct 8, 2026 | 48 |
| Oct 7, 2026 | 48 |
| Oct 6, 2026 | 47 |
| Oct 5, 2026 | 47 |
| Oct 4, 2026 | 49 |
| Oct 3, 2026 | 49 |
| Oct 2, 2026 | 49 |
| Oct 1, 2026 | 50 |
| Sep 30, 2026 | 51 |
| Sep 29, 2026 | 49 |
| Sep 28, 2026 | 51 |
| Sep 27, 2026 | 50 |
| Sep 26, 2026 | 50 |
| Sep 25, 2026 | 50 |
| Sep 24, 2026 | 51 |
| Sep 23, 2026 | 53 |
| Sep 22, 2026 | 53 |
| Sep 21, 2026 | 54 |
| Sep 20, 2026 | 53 |
| Sep 19, 2026 | 53 |
| Sep 18, 2026 | 52 |
| Sep 17, 2026 | 52 |
| Sep 16, 2026 | 52 |
| Sep 15, 2026 | 53 |
| Sep 14, 2026 | 53 |
| Sep 13, 2026 | 53 |
| Sep 12, 2026 | 53 |
| Sep 11, 2026 | 53 |
| Sep 10, 2026 | 53 |
| Sep 9, 2026 | 54 |
| Sep 8, 2026 | 57 |
| Sep 7, 2026 | 57 |
| Sep 6, 2026 | 57 |
| Sep 5, 2026 | 57 |
| Sep 4, 2026 | 55 |
| Sep 2, 2026 | 57 |
| Sep 1, 2026 | 56 |
| Aug 31, 2026 | 55 |
| Aug 30, 2026 | 56 |
| Aug 29, 2026 | 55 |
| Aug 28, 2026 | 55 |
| Aug 27, 2026 | 56 |
| Aug 26, 2026 | 56 |
| Aug 25, 2026 | 57 |
| Aug 24, 2026 | 56 |
| Aug 23, 2026 | 56 |
Key facts
- Market cap
- $1.3B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- —
- Risk grade (1–10)
- 8
- Next earnings
- Nov 12, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| NTLA Intellia Therapeutics | $1.3B | 33 |
| INVA Innoviva | $1.3B | 63 |
| OCUL Ocular Therapeutix | $1.3B | 38 |
| GHRS GH Research | $1.3B | 42 |
| NVAX Novavax | $1.3B | 55 |
| MNKD MannKind | $1.3B | 56 |
Questions
What is LBRX's stock rating today?
LBRX scores 41/100 (Weak) as of Nov 19, 2026: technical 54, fundamental 37, and news sentiment 51, which is shown but not counted. Scores are recomputed every night.
What does LB Pharmaceuticals do?
LB Pharmaceuticals (LBRX) is a clinical-stage biopharmaceutical company developing new treatments for schizophrenia and other neuropsychiatric disorders. Its lead candidate, LB-102, is a once-daily oral drug from the benzamide class, related to amisulpride, an antipsychotic used outside the United States that has not been approved here for psychiatric use.
Is LBRX stock a buy?
The score is not a buy or sell recommendation. A 41 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the LBRX score calculated?
88 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/lbrx/"><img src="https://stocksscores.com/stocks/lbrx/badge.svg" alt="LBRX stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/lbrx/)